Tags

Type your tag names separated by a space and hit enter

Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes.

Abstract

OBJECTIVE

Our objective was to assess effects of dietary supplementation with coenzyme Q10 (CoQ) on blood pressure and glycaemic control in subjects with type 2 diabetes, and to consider oxidative stress as a potential mechanism for any effects.

SUBJECTS AND DESIGN

Seventy-four subjects with uncomplicated type 2 diabetes and dyslipidaemia were involved in a randomised double blind placebo-controlled 2x2 factorial intervention.

SETTING

The study was performed at the University of Western Australia, Department of Medicine at Royal Perth Hospital, Australia.

INTERVENTIONS

Subjects were randomly assigned to receive an oral dose of 100 mg CoQ twice daily (200 mg/day), 200 mg fenofibrate each morning, both or neither for 12 weeks.

MAIN OUTCOME MEASURES

We report an analysis and discussion of the effects of CoQ on blood pressure, on long-term glycaemic control measured by glycated haemoglobin (HbA(1c)), and on oxidative stress assessed by measurement of plasma F2-isoprostanes.

RESULTS

Fenofibrate did not alter blood pressure, HbA(1c), or plasma F2-isoprostanes. There was a 3-fold increase in plasma CoQ concentration (3.4+/-0.3 micro mol/l, P<0.001) as a result of CoQ supplementation. The main effect of CoQ was to significantly decrease systolic (-6.1+/-2.6 mmHg, P=0.021) and diastolic (-2.9+/-1.4 mmHg, P=0.048) blood pressure and HbA(1c) (-0.37+/-0.17%, P=0.032). Plasma F2-isoprostane concentrations were not altered by CoQ (0.14+/-0.15 nmol/l, P=0.345).

CONCLUSIONS

These results show that CoQ supplementation may improve blood pressure and long-term glycaemic control in subjects with type 2 diabetes, but these improvements were not associated with reduced oxidative stress, as assessed by F2-isoprostanes.

SPONSORSHIP

This study was supported by a grant from the NH&MRC, Australia.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    University of Western Australia Department of Medicine and HeartSearch, Royal Perth Hospital, Perth, Western Australia, Australia.

    , , ,

    Source

    European journal of clinical nutrition 56:11 2002 Nov pg 1137-42

    MeSH

    Antioxidants
    Blood Glucose
    Blood Pressure
    Coenzymes
    Diabetes Mellitus, Type 2
    Dietary Supplements
    Double-Blind Method
    F2-Isoprostanes
    Female
    Fenofibrate
    Glycated Hemoglobin A
    Humans
    Hyperlipidemias
    Hypolipidemic Agents
    Male
    Middle Aged
    Oxidative Stress
    Ubiquinone

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    12428181

    Citation

    Hodgson, J M., et al. "Coenzyme Q10 Improves Blood Pressure and Glycaemic Control: a Controlled Trial in Subjects With Type 2 Diabetes." European Journal of Clinical Nutrition, vol. 56, no. 11, 2002, pp. 1137-42.
    Hodgson JM, Watts GF, Playford DA, et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr. 2002;56(11):1137-42.
    Hodgson, J. M., Watts, G. F., Playford, D. A., Burke, V., & Croft, K. D. (2002). Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. European Journal of Clinical Nutrition, 56(11), pp. 1137-42.
    Hodgson JM, et al. Coenzyme Q10 Improves Blood Pressure and Glycaemic Control: a Controlled Trial in Subjects With Type 2 Diabetes. Eur J Clin Nutr. 2002;56(11):1137-42. PubMed PMID: 12428181.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. AU - Hodgson,J M, AU - Watts,G F, AU - Playford,D A, AU - Burke,V, AU - Croft,K D, PY - 2002/11/13/pubmed PY - 2003/4/11/medline PY - 2002/11/13/entrez SP - 1137 EP - 42 JF - European journal of clinical nutrition JO - Eur J Clin Nutr VL - 56 IS - 11 N2 - OBJECTIVE: Our objective was to assess effects of dietary supplementation with coenzyme Q10 (CoQ) on blood pressure and glycaemic control in subjects with type 2 diabetes, and to consider oxidative stress as a potential mechanism for any effects. SUBJECTS AND DESIGN: Seventy-four subjects with uncomplicated type 2 diabetes and dyslipidaemia were involved in a randomised double blind placebo-controlled 2x2 factorial intervention. SETTING: The study was performed at the University of Western Australia, Department of Medicine at Royal Perth Hospital, Australia. INTERVENTIONS: Subjects were randomly assigned to receive an oral dose of 100 mg CoQ twice daily (200 mg/day), 200 mg fenofibrate each morning, both or neither for 12 weeks. MAIN OUTCOME MEASURES: We report an analysis and discussion of the effects of CoQ on blood pressure, on long-term glycaemic control measured by glycated haemoglobin (HbA(1c)), and on oxidative stress assessed by measurement of plasma F2-isoprostanes. RESULTS: Fenofibrate did not alter blood pressure, HbA(1c), or plasma F2-isoprostanes. There was a 3-fold increase in plasma CoQ concentration (3.4+/-0.3 micro mol/l, P<0.001) as a result of CoQ supplementation. The main effect of CoQ was to significantly decrease systolic (-6.1+/-2.6 mmHg, P=0.021) and diastolic (-2.9+/-1.4 mmHg, P=0.048) blood pressure and HbA(1c) (-0.37+/-0.17%, P=0.032). Plasma F2-isoprostane concentrations were not altered by CoQ (0.14+/-0.15 nmol/l, P=0.345). CONCLUSIONS: These results show that CoQ supplementation may improve blood pressure and long-term glycaemic control in subjects with type 2 diabetes, but these improvements were not associated with reduced oxidative stress, as assessed by F2-isoprostanes. SPONSORSHIP: This study was supported by a grant from the NH&MRC, Australia. SN - 0954-3007 UR - https://www.unboundmedicine.com/medline/citation/12428181/Coenzyme_Q10_improves_blood_pressure_and_glycaemic_control:_a_controlled_trial_in_subjects_with_type_2_diabetes_ L2 - http://dx.doi.org/10.1038/sj.ejcn.1601464 DB - PRIME DP - Unbound Medicine ER -